FDA Starts Its Second Safety Investigation Into Novartis/Orion's Parkinson's Drug Stalevo

An FDA meta-analysis reveals a cardiovascular safety risk with Orion and Novartis' Stalevo, on top of an ongoing review of a prostate cancer imbalance, but uncertainty about the data raises the question of whether FDA will want a prospective heart safety study.